Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 7/20 | 0.52 |
| ▸ | MMP13 | P45452 | 5/20 | 0.52 |
| ▸ | MMP2 | P08253 | 11/20 | 0.45 |
| ▸ | MMP9 | P14780 | 11/20 | 0.45 |
| ▸ | MMP8 | P22894 | 4/20 | 0.45 |
| ▸ | MMP14 | P50281 | 4/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | MMP3 | P08254 | 2/20 | 0.42 |
| ▸ | MMP7 | P09237 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7345951 | 0.86 | MMP12 (0.50) | MMP12MMP13MMP2MMP9MMP8 | |
| SCHEMBL7344147 | 0.83 | MMP12 (0.47) | MMP12MMP13MMP2MMP9MMP8 | |
| SCHEMBL7350497 | 0.83 | MMP12 (0.50) | MMP12MMP13MMP2MMP9MMP8 | |
| SCHEMBL7352548 | 0.82 | MMP12 (0.53) | MMP12MMP13MMP2MMP9MMP8 | |
| SCHEMBL7352152 | 0.82 | MMP12 (0.53) | MMP12MMP13MMP2MMP9MMP8 | |
| SCHEMBL7351458 | 0.82 | MMP12 (0.53) | MMP12MMP13MMP2MMP9MMP8 | |
| SCHEMBL7347007 | 0.82 | MMP13 (0.57) | MMP12MMP13MMP2MMP9MMP8 | |
| SCHEMBL7372175 | 0.81 | MMP2 (0.53) | MMP12MMP13MMP2MMP9MMP8 | |
| SCHEMBL7349084 | 0.81 | MMP2 (0.52) | MMP12MMP13MMP2MMP9MMP8 | |
| SCHEMBL6413671 | 0.81 | MMP12 (0.69) | MMP12MMP13POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6294674-B1 | FOR THERAPY OF MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, RESTENOSIS, AORTIC ANEURISM, HEART FAILURE, PERIODONTAL DISEASE, CORNEAL ULCERATION, BURNS, DECUBITAL ULCERS, CHRONIC ULCERS OR WOUNDS, CANCER METASTASIS | WARNER-LAMBERT COMPANY | 2001-09-25 | — | — | US | claimed |
| EP-0929542-A1 | COMPOUNDS FOR AND A METHOD OF INHIBITING MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1999-07-21 | — | — | EP | claimed |
| WO-1998009957-A1 | COMPOUNDS FOR AND A METHOD OF INHIBITING MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | claimed |
| US-6294674-B1 | FOR THERAPY OF MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, RESTENOSIS, AORTIC ANEURISM, HEART FAILURE, PERIODONTAL DISEASE, CORNEAL ULCERATION, BURNS, DECUBITAL ULCERS, CHRONIC ULCERS OR WOUNDS, CANCER METASTASIS | WARNER-LAMBERT COMPANY | 2001-09-25 | — | — | US | disclosed |
| EP-0929542-A1 | COMPOUNDS FOR AND A METHOD OF INHIBITING MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1999-07-21 | — | — | EP | disclosed |
| WO-1998009957-A1 | COMPOUNDS FOR AND A METHOD OF INHIBITING MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |